Corporate Presentation

Investor Relations

Corporate & Pipeline Overview

KIO-401 In-Licensing

October 29, 2026

Company Overview

Kiora Pharmaceuticals is a late-stage retinal therapeutics company developing small-molecule therapies targeting differentiated biological pathways implicated in vision-threatening diseases.

KIO-401 is an oral, neuroprotective calpain inhibitor in development for central retinal artery occlusion (CRAO) and non-arteritic anterior ischemic optic neuropathy (NAION), two rare, acute ischemic ophthalmic diseases with no approved pharmacologic treatments. Kiora is planning a multinational Phase 3 registration trial in CRAO and a Phase 2b clinical trial in NAION. The KIO-401 platform also has potential applications in additional ophthalmic indications, including glaucoma, where calpain-mediated injury may contribute to disease progression.

KIO-301 is a partnered Phase 2 photoswitch therapy for advanced retinitis pigmentosa. KIO-104, a DHODH inhibitor previously evaluated in the KLARITY clinical trial for retinal inflammation and fibrosis, is available for partnering or out-licensing.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Stock Snapshot

IR Contacts

Headquarters

Kiora Pharmaceuticals, Inc.
169 Saxony Rd
Suite 212
Encinitas, CA 92024

Investor Relations

investors@kiorapharma.com